Metoclopramide Shortage: What Providers and Prescribers Need to Know in 2026

While oral metoclopramide is not currently listed on the FDA Drug Shortages Database for 2026, prescribers are still fielding calls from patients who cannot locate this medication at their local pharmacy. This article provides clinical guidance for managing patients affected by localized metoclopramide supply gaps, with a focus on therapeutic alternatives, formulary considerations, and patient communication strategies.

Current Availability Status by Formulation

As of 2026, the availability picture for metoclopramide formulations is as follows:

• Oral tablets (5 mg, 10 mg): Not on FDA shortage. Multiple generic manufacturers. Generally available at major retail pharmacies, though individual stores may have stock gaps.
• Orally disintegrating tablets (5 mg, 10 mg): Not on FDA shortage, but stocked less universally. Some pharmacies may need to special-order.
• Oral solution (5 mg/5 mL): Limited stocking at retail pharmacies; may require special order or mail-order.
• Injectable (5 mg/mL): Has historically appeared on ASHP shortage notices. Check current ASHP Drug Shortage Resource Center for the most up-to-date hospital formulary status.

Why Patients May Still Report Difficulty Finding Oral Metoclopramide

Demand displacement from the ongoing prochlorperazine shortage is a significant driver. As of early 2026, prochlorperazine (Compazine) tablets and injectable forms remain on ASHP shortage lists. Clinicians substituting metoclopramide for prochlorperazine — in gastroparesis, chemotherapy-related nausea, and ED migraine protocols — have created localized demand spikes at retail pharmacies. Prescribers should be aware of this dynamic and consider broader therapeutic alternatives rather than simply defaulting to metoclopramide as the prochlorperazine substitute.

Therapeutic Alternatives by Indication

For Diabetic Gastroparesis

Metoclopramide remains the only FDA-approved oral medication for diabetic gastroparesis (as of 2026). Alternatives are off-label:

• Erythromycin (125–250 mg PO TID-QID before meals): Motilin receptor agonist; short-term use due to tachyphylaxis (typically 4–8 weeks before reduced efficacy). Monitor for QTc prolongation and CYP3A4 interactions.
• Domperidone (10–20 mg PO TID-QID): Not FDA-approved; available through expanded access IND. Potentially lower CNS side-effect profile. Requires QTc monitoring.
• Dietary modification: Small, frequent, low-fat, low-fiber meals remain a cornerstone of gastroparesis management. Consider dietitian referral.

For GERD (Failed Conventional Therapy)

For patients using metoclopramide as adjunct therapy for GERD unresponsive to PPIs or H2 blockers:

• Optimize PPI/H2 blocker dosing before considering metoclopramide alternatives.
• Baclofen (5–20 mg TID): Reduces transient lower esophageal sphincter relaxations off-label; can be considered in refractory GERD.

For Chemotherapy-Induced Nausea and Vomiting (CINV)

Current NCCN guidelines prefer 5-HT3 antagonists and NK1 antagonists for CINV over dopamine antagonists. If switching from parenteral metoclopramide is necessary:

• Ondansetron 8–32 mg IV/PO (5-HT3 antagonist)
• Granisetron, palonosetron (5-HT3 antagonists with varying half-lives)
• Aprepitant/fosaprepitant (NK1 antagonist) — for highly emetogenic regimens

For ED/Urgent Care Migraine Management

When IV metoclopramide is unavailable in the ED setting:

• Ondansetron 4–8 mg IV — antiemetic component only
• Haloperidol 0.5–2 mg IV — evidence-based for ED migraine; D2 antagonism similar to metoclopramide
• Ketorolac 15–30 mg IV — non-dopaminergic analgesic alternative

Key Prescribing Reminders for Metoclopramide in 2026

1. 12-week limit: Avoid treatment beyond 12 weeks except in rare cases where benefit outweighs TD risk. Document clinical justification for extended use.
2. CYP2D6 poor metabolizers: Reduce dose in patients who are CYP2D6 poor metabolizers or who are on strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine).
3. Renal impairment: Reduce dose by 50% in patients with CrCl <40 mL/min.
4. Elderly patients: Listed on the AGS Beers Criteria as a potentially inappropriate medication. Older adults — especially women — have higher TD risk. Use the lowest effective dose and monitor closely.
5. Concomitant antipsychotics: Avoid concurrent use — additive TD/EPS/NMS risk.

Helping Your Patients Find Metoclopramide

When patients cannot fill their prescription at their usual pharmacy, medfinder for Providers offers a streamlined way to identify retail pharmacies with current metoclopramide stock. Your team can direct patients to use the service rather than spending valuable appointment time troubleshooting pharmacy inventory issues.

For a complete workflow guide, see How to Help Your Patients Find Metoclopramide in Stock: A Provider's Guide.